Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

13 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

CALGB: 80405 FOLLOW-UP AND RESPONSE FORM NCT00265850

- 08/06/2015 - 1 Formulário, 5 Grupos de itens, 29 Elementos de dados, 1 Idioma
Grupos de itens: Header, Patient demographics, Patient status assessment, RESPONSE DATA, NEW PRIMARY DATA
CALGB: 80405 FOLLOW-UP AND RESPONSE FORM NCT00265850 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F39BEECE-F2C5-5BE1-E034-0003BA3F9857

Southwest Oncology Group Follow-Up Tumor Assessment Form

- 03/07/2015 - 1 Formulário, 7 Grupos de itens, 26 Elementos de dados, 1 Idioma
Grupos de itens: SWOG clinical trial administrative data, Target Lesions, Non-target Disease, New Lesions, Symptomatic deterioration, Comments, CCRR MODULE
Southwest Oncology Group Follow-Up Tumor Assessment Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A50B6C19-55BD-164C-E034-080020C9C0E0

SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR ASSESSMENT FORM

- 12/06/2015 - 1 Formulário, 6 Grupos de itens, 24 Elementos de dados, 1 Idioma
Grupos de itens: Header, TARGET LESIONS, NON-TARGET DISEASE, NEW LESIONS (specify site), Symptomatic deterioration, Comments
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR ASSESSMENT FORM Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F4422C8B-0D37-49D1-E034-0003BA3F9857

Response - Follow-Up Solid Tumor Evaluation Form - 2264083v3.0 - Follow-Up Solid Tumor Evaluation Form

- 08/01/2015 - 1 Formulário, 7 Grupos de itens, 38 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Form Administration, Target Lesion(s) Follow-up Evaluation, Nontarget Lesion(s) Follow-up Evaluation, New Lesion(s) at Follow-up Evaluation, Evaluation Summary, Comments
Follow-Up Solid Tumor Evaluation Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D8887F28-3F68-039E-E034-0003BA12F5E7

SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR ASSESSMENT FORM NCT00045162

- 09/06/2015 - 1 Formulário, 6 Grupos de itens, 24 Elementos de dados, 1 Idioma
Grupos de itens: Header, TARGET LESIONS, NON-TARGET DISEASE, NEW LESIONS (specify site), Symptomatic deterioration, Comments
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR ASSESSMENT FORM NCT00045162 S0124: Cisplatin Combined With Either Irinotecan or Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=001B724F-E7F0-4714-E044-0003BA3F9857

CALGB: 90202 Follow-up Solid Tumor Evaluation Form NCT00079001

- 08/06/2015 - 1 Formulário, 6 Grupos de itens, 33 Elementos de dados, 1 Idioma
Grupos de itens: Header, Patient demographics, Reporting Period, Target Lesion(s) Follow-up Evaluation, Non-target lesion(s) Follow-up Evaluation, CCRR MODULE
CALGB: 90202 Follow-up Solid Tumor Evaluation Form NCT00079001 Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B460627D-9F78-051C-E034-0003BA12F5E7

Response - Multiple Myeloma - Follow-Up Disease Assessment Form - 2274798v3.0 - Multiple Myeloma - Follow-Up Disease Assessment Form

- 09/01/2015 - 1 Formulário, 9 Grupos de itens, 82 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Myeloma: Form Administration, Myeloma: Assessment Reporting Interval, Myeloma: Protein Studies Response, Myeloma: Peripheral Blood Hematology/Chemistry, Myeloma: Bone and Marrow Response Assessment, Myeloma: Soft Tissue Plasmacytoma Response, Myeloma: Objective Response Assessment, Comments
Multiple Myeloma - Follow-Up Disease Assessment Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D6E34646-3810-5812-E034-0003BA12F5E7

Response - Waldenstroms Macroglobulinemia - Follow-Up Disease Assessment Form - 2276095v3.0 - Waldenstroms Macroglobulinemia - Follow-Up Disease Assessment Form

- 09/01/2015 - 1 Formulário, 9 Grupos de itens, 69 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Waldenstrom's: Form Administration, Waldenstrom's: Assessment Reporting Interval, Waldenstrom's: Peripheral Blood Hematology/Chemistry, Waldenstrom's: Protein Studies, Waldenstrom's: Bone Marrow Assessment, Waldenstrom's: Liver, Spleen, and Node Assessment, Waldenstrom's: Objective Response Assessment, Comments
Waldenstrom's Macroglobulinemia - Follow-Up Disease Assessment Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D6E2F0A5-966B-5DD3-E034-0003BA12F5E7

Response - Primary Amyloidosis - Follow-Up Disease Assessment Form - 2275307v3.0 - Primary Amyloidosis - Follow-Up Disease Assessment Form

- 09/01/2015 - 1 Formulário, 10 Grupos de itens, 94 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Amyloid: Form Administration, Amyloid: Assessment Reporting Interval, Amyloid: Protein Studies, Amyloid: Peripheral Blood Hematology/Chemistry, Amyloid: Organ Assessment, Amyloid: Bone Marrow Assessment, Amyloid: Amyloidoma, Amyloid: Objective Response Assessment, Comments
Primary Amyloidosis - Follow-Up Disease Assessment Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D6E37EC9-1337-59D5-E034-0003BA12F5E7

Response - Hodgkins Lymphoma - Follow-Up Disease Assessment Form - 2269525v3.0 - Hodgkins Lymphoma - Follow-Up Disease Assessment Form

- 09/01/2015 - 1 Formulário, 8 Grupos de itens, 57 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Lymphoma: Form Administration, Lymphoma: Measurable Disease Response, Lymphoma: Non-Measurable Disease Response, Lymphoma: New Lesions, Lymphoma: Bone Marrow and Liver Assessment, Hodgkin's Lymphoma: Biochemical and B Symptoms, Hodgkin's Lymphoma: Response Assessment
Hodgkin's Lymphoma - Follow-Up Disease Assessment Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D5EB536B-A765-64B5-E034-0003BA12F5E7

Response - Non-Hodgkins Lymphoma - Follow-Up Disease Assessment Form - 2270621v3.0 - Non-Hodgkins Lymphoma - Follow-Up Disease Assessment Form

- 09/01/2015 - 1 Formulário, 10 Grupos de itens, 88 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Lymphoma: Form Administration, Lymphoma: Dominant Node Response, Lymphoma: Nondominant Lesion Response, Lymphoma: Measurable Hepatic/Splenic Nodule Response, Lymphoma: Non-Measurable Lesion Response, Lymphoma: New Lesions, Lymphoma: Bone Marrow, Liver and Spleen Response Assessment, Non-Hodgkin's Lymphoma: Biochemical and B Symptoms, Non-Hodgkin's Lymphoma: Response Assessment
Non-Hodgkin's Lymphoma - Follow-Up Disease Assessment Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D5EC0BF1-C6F3-750B-E034-0003BA12F5E7

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Post Treatment Response - Follow-Up

- 25/07/2018 - 1 Formulário, 10 Grupos de itens, 39 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Diagnostic Imaging, Head/Neck, Diagnostic Imaging; Chest, Diagnostic Imaging, Abdomen, Diagnostic Imaging, Pelvis, Diagnostic Imaging, Other, Bone Marrow Biopsy, Measurable Lymphoma Disease, Non-Measurable Disease, Response to treatment
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial